Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: Potential pluses and minuses

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 8, 2010, Pages 881-885

  Johnson Jahangir, Hillary ^a   Sherman, William ^a   Ratner, Désirée ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Dermatofibrosarcoma protuberans; Imatinib; Mohs micrographic surgery; Neoadjuvant; Platelet derived growth factor

Indexed keywords

IMATINIB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; EDEMA; FATIGUE; GASTROINTESTINAL IRRITATION; HUMAN; MACULOPAPULAR RASH; MORBIDITY; MULTIPLE ORGAN FAILURE; MYALGIA; PATHOGENESIS; PERIPHERAL EDEMA; STEVENS JOHNSON SYNDROME; TUMOR VOLUME; XEROSIS;

EID: 77957350874     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0065     Document Type: Article

References (39)

1. Mori T, Misago N, Yamamoto O, et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. J Dermatol 2008;35:419-425.
2. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007;56:968-973.
3. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35(3 Pt 1):355-374; quiz 375-376.
4. Weinstein JM, Drolet BA, Esterly NB. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003;139:207-211. (Pubitemid 36216259)
5. Maire G, Fraitag S, Galmiche L, et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 2007;143:203-210.
6. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-2720.
7. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005;23:7669-7675.
8. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998;22:576-587.
9. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;100:1008-1016.
10. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010;17:2112-2118.
11. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600-613.
12. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:82-87.
13. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004;101:28-38.
14. Hancox JG, Kelley B, Greenway HT Jr. Treatment of dermatofibroma sarcoma protuberans using modified Mohs micrographic surgery: no recurrences and smaller defects. Dermatol Surg 2008;34:780-784.
15. Pedeutour F, Coindre JM, Sozzi G, et al. Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogenet 1994;76:1-9.
16. Naeem R, Lux ML, Huang SF, et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995;47:1553-1558.
17. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999;59:3719-3723.
18. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008;39:184-193.
19. Llombart B, Sanmartin O, Lopez-Guerrero JA, et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology 2009;54:860-872.
20. Capdeville R, Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol 2003;40(2 Suppl 2):15-20. (Pubitemid 36687154)
21. Gleevec (imatinib mesylate). U.S. Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Overview&DrugName=GLEEVEC. Accessed April 7, 2010.
22. Miller SJ, Alam M, Andersen J, et al. NCCN clinical practice guidelines in oncology: dermatofibrosarcoma protuberans. Version 1, 2010. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed April 7, 2010.
23. Lemm D, Mugge LO, Mentzel T, Hoffken K. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009;135:653-665.
24. McArthur GA. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Cane Netw 2007;5:557-562.
25. McArthur G. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol 2007;14:2876-2886.
26. Abrams TA, Schuetze SM. Targeted therapy for dermatofibrosarcoma protuberans. Curr Oncol Rep 2006;8:291-296.
27. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28:1772-1779.
28. Haycox CL, Odland PB, Olbricht SM, Piepkorn M. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997;37(3 Pt 1):438-444.
29. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-626.
30. Han A, Chen EH, Niedt G, et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009;145:792-796.
31. Sciot R, Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol 2006;23:84-90.
32. Thomison J, McCarter M, McClain D, et al. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol 2008;35:1003-1006.
33. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-873.
34. Mehrany K, Swanson NA, Heinrich MC, et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006;32:456-459.
35. Wright TI, Petersen JE. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007;33:741-744.
36. Lemm D, Muegge LO, Hoeffken K, et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans - a case report. Oral Maxillofac Surg 2008;12:209-213.
37. Mattox AK, Mehta AI, Grossi PM, et al. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. J Neurosurg 2010;112:965-977.
38. Wolf D, Rumpold H. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf 2009;32:1001-1015.
39. Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009;23:1537-1544.